Journal
MOLECULAR MEDICINE
Volume 15, Issue 7-8, Pages 195-202Publisher
SPRINGER
DOI: 10.2119/molmed.2009.00039
Keywords
-
Funding
- NIGMS NIH HHS [R01 GM057226-10, R01 GM057226] Funding Source: Medline
Ask authors/readers for more resources
The cholinergic antiinflammatory pathway modulates inflammatory cytokine production through a mechanism dependent on the vagus nerve and the alpha 7 subunit of the nicotinic acetylcholine receptor. GTS-21 (3-(2,4-dimethoxybenzylidene) anabaseine), a selective alpha 7 agonist, inhibits inflammatory cytokine production in murine and human macrophages and in several models of inflammatory disease in viva but to date its antiinflammatory efficacy in human monocytes has not been characterized. We report here our findings that GTS-21 attenuates tumor necrosis factor (TNF) and interleukin 1 beta 0 levels in human whole blood activated by exposure to endotoxin. GTS-21 inhibited TNF production in endotoxin-stimulated primary human monocytes in vitro at the transcriptional level. The suppressive effect of GTS-21 was more potent than nicotine in whole blood and monocytes. Furthermore, GTS-21 attenuated TNF production in monocytes stimulated with peptidoglycan, polyinosinic-polycytidylic acid, CpG, HMGB1 (high-mobility group box 1 protein), and advanced glycation end product-modified albumin. GTS-21 decreased TNF levels in endotoxin-stimulated whole blood obtained from patients with severe sepsis. These findings establish the immunoregulatory effect of GTS-21 on human monocytes, and indicate the potential benefits of further exploration of GTS-21's therapeutic uses in human inflammatory disease. (C) 2009 The Feinstein Institute for Medical Research, www.feinsteininstitute.org Online address: http://www.molmed.org doi: 10.2119/molmed.2009.00039
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available